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Mounting evidence shows that brain disorders involve multiple and different neural
dysfunctions, including regional brain damage, change to cell structure, chemical
imbalance, and/or connectivity loss among different brain regions. Understanding the
complexity of brain disorders can help us map these neural dysfunctions to different
symptom clusters as well as understand subcategories of different brain disorders.
Here, we discuss data on the mapping of symptom clusters to different neural
dysfunctions using examples from brain disorders such as major depressive disorder
(MDD), Parkinson’s disease (PD), schizophrenia, posttraumatic stress disorder (PTSD)
and Alzheimer’s disease (AD). In addition, we discuss data on the similarities of
symptoms in different disorders. Importantly, computational modeling work may be able
to shed light on plausible links between various symptoms and neural damage in brain
disorders.
Keywords: brain disorders, functional connectivity, neurotransmitters, regional brain volume, major depressive
disorder, Parkinson’s disease, schizophrenia, posttraumatic stress disorder
INTRODUCTION
Brain disorders are associated with several symptom clusters as well as many neural dysfunctions.
For example, although Parkinson’s disease (PD) is associated with reduced dopamine levels in the
brain (Kish et al., 1988), studies found other neural dysfunctions including abnormal subthalamic
nucleus oscillations as well as changes in cortical and cerebellar structures (Levy et al., 2000;
Wu and Hallett, 2013). Further, PD is associated with different classes of motor symptoms,
including akinesia, bradykinesia, tremor, and medication-induced dyskinesia. These symptoms
are caused by a somewhat different neural abnormalities (which we will discuss this below).
The same applies to Alzheimer’s disease (AD) as it involves many symptom clusters (including
memory loss, apraxia, language impairment, and executive dysfunction) and multiple neural
abnormalities including damage in the hippocampus and neocortex (Wilcock and Esiri, 1982).
Similarly, psychiatric disorders are characterized by various psychopathological symptoms with
complex underlying neural substrates. Major depressive disorder (MDD), for example, is associated
with mood, physical, and cognitive changes, among other behavioral symptoms (Nutt et al., 2007).
At the neural level, MDD symptoms are associated withreduced levels of dopamine and serotonin
as well as decreased volumes of the hippocampus and prefrontal cortex (Drevets et al., 2008).
Similarly (and rather unsurprisingly), posttraumatic stress disorder (PTSD) and schizophrenia
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are associated with various symptom clusters (i.e., positive
vs. negative symptoms in schizophrenia, and avoidance vs.
re-experiencing in PTSD); both disorders are associated with
widespread neural damage. Unlike MDD and PD, there
have been a larger number of studies that attempt to
map schizophrenia symptoms to dissociable neural substrates
(Wolkin et al., 1992; Buchanan et al., 1993; Okubo et al., 1997;
Abi-Dargham, 2003; Rueter et al., 2004; Cascella et al., 2008;
Farkas et al., 2008; Kéri, 2008; Polgár et al., 2010; Arnedo et al.,
2015).
Below, we discuss various symptom clusters, what we
know about their neural substrates, as well as potential
computational modeling work to help understand behavioral-
neural relationships in the following brain disorders: MDD, PD,
AD, PTSD and schizophrenia.
COMPUTATIONAL MODELING
For many years now, the importance of dysfunctional neural
circuits and/or brain regions is being underlined when
considering the pathophysiological mechanisms underpinning
psychopathological symptoms of neuropsychiatric disorders.
However, inter- and intra-regional neural connections and
disconnections are still poorly understood at the present time.
In order to shed more light on the neurobiological substrates
of neuropsychiatric symptomatology, computational models
rooted in translational cognitive neuroscience are being created
in order to explain variety of behavioral, neurophysiological
and neuroanatomical data (Eliasmith et al., 2012; Rasmussen
and Eliasmith, 2013). Computational models usually consist of
reciprocally connected loops between different circuits with top-
down and bottom-up signaling at the cortical and subcortical
levels (McClelland et al., 1995; O’Reilly and Norman, 2002;
Bobier et al., 2014). In the current literature, the most commonly
applied models are reinforcement learning models – allowing to
analyze key aspects of choice, and Bayesian models – formalizing
main aspects of the inference prior beliefs with current sensory
data, each weighted according to their uncertainty (Pauli et al.,
2012). Recent developments in this area demonstrate that such
models hold potential to expand our understanding of neurologic
and psychiatric disorders (Frank et al., 2012; Adams et al.,
2016).
MAJOR DEPRESSIVE DISORDER
MDD is a psychiatric disorder characterized by reduced mood,
anhedonia, psychomotor retardation, and learned helplessness,
among others (Kennedy, 2008). It is known that MDD involves
changes to different neurotransmitters, while the most salient
change is to serotonin. There are also changes to dopaminergic
and noradrenergic transmission (Nutt, 2008). MDD is also
associated with changes to brain volumes and connectivity
networks among different brain regions. For example, studies
have reported reduced gray matter volume in the anterior
cingulate (van Tol et al., 2010) and hippocampus (Videbech
and Ravnkilde, 2004) in patients with MDD. Other studies
reported increased connectivity among the anterior cingulate
and medial temporal lobe (de Kwaasteniet et al., 2013), while
others reported a decrease in the functional connectivity in
the insula and amygdala (Veer et al., 2010). These findings
highlight the fact that MDD is associated with multiple
neural dysfunctions. These previously mentioned studies did
not, however, map these neural abnormalities to specific
symptoms in depression. However, there are some studies
that have attempted to understand the neural correlates
for each symptom in depression (Vrieze et al., 2014). For
example, Argyropoulos and Nutt (2013) found that anhedonia
(the inability to experience pleasure) is related to dopamine
reduction, while reduced mood is related to decreased serotonin
levels. Some studies have investigated the neural substrates
of psychomotor retardation (lack of energy and reduced
movement) in depression, and suggested that reduced dopamine
is also implicated (Liberg and Rahm, 2015). It is possible that
reduced dopamine levels in the ventral striatum is related
to anhedonia whereas reduced dopamine levels in the dorsal
striatum is related to psychomotor retardation (Stein, 2008).
In addition, it was suggested that reduced mood and sadness
in MDD is associated with dysfunction in the prefrontal
cortex, particularly, the orbitofrontal cortex (Drevets, 1999;
Mayberg et al., 1999; Davidson et al., 2002; Drevets et al.,
2002; Lévesque et al., 2003). Although the studies mentioned
above have mapped certain symptoms of MDD to separable
neural dysfunctions, the exact mechanism of these observations
remains unclear. Computational modeling work should attempt
to explain the behavioral-neural relationships, such as how a
reduction of dopamine in the striatum leads to psychomotor
retardation.
The concept that depression is accompanied by a
dysfunctional reward system has been shown empirically
numerous times over past years (for review, see Chen et al.,
2015). Using prediction error learning algorithm to model
behavioral performance in MDD, Steele et al. (2007) have shown
that speeding of reaction times after wins and slowing after
loses were not as pronounced as in the healthy control subjects.
Moreover, this feedback-related speeding/slowing effect was
associated with anhedonia. In the meta-analytic study performed
by Huys et al. (2013) showed that anhedonia in depressive
states is mediated by a change in reward sensitivity, which is
different from either stress or dopamine manipulations, such
as receiving dopamine D2 agonists. Additionally, he has shown
that anhedonia affect appetitive learning more by reducing the
primary sensitivity to rewards than by affecting the learning
rates.
PARKINSON’S DISEASE
PD is characterized by tremor, akinesia, rigidity, bradykinesia,
and gait dysfunction among other symptoms (Kish et al., 1988).
Beside reduction of dopamine levels, PD also involves changes
in neural volumes and connectivity among brain regions (Shine
et al., 2013). This is accompanied with changes to medium
spiny neurons in the striatum due to dopamine degeneration
(Villalba and Smith, 2010). PD patients are often categorized
into akinesia-dominant vs. tremor-domanient (Rajput et al.,
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2009; Zaidel et al., 2009; Moustafa et al., 2013a). It has been
shown that motor symptoms in PD map to different neural
dysfunctions. For example, akinesia and bradykinesia have been
shown to be related to dopamine reduction in the basal ganglia
(Albin et al., 1989; Spiegel et al., 2007; Rodriguez-Oroz et al.,
2009; Rossi et al., 2010; Helmich et al., 2011), while tremor is
related to abnormalities to the subthalamic nucleus, thalamus
and cerebellum (Deuschl et al., 1998, 2000; Helmich et al., 2012).
To complicate the picture, tremor has been often divided
into three subtypes: resting, action, and postural (Helmich et al.,
2012). Another less common categorization method of tremor
also includes a fourth category: intention tremor (Fahn, 2011).
Other studies also categorize tremor based on its frequency
(low or high) and body parts affected (hand, leg, or other).
Some studies have suggested action and resting tremor can stem
from dissociable neural systems (Raethjen et al., 2000; Cagnan
et al., 2014). However, the exact mechanism of how neural
abnormalities can generate either resting and action tremor is
not known, but computational modeling work can shed light on
these issues.
Other motor symptoms in PD were found to be impacted
by other neural systems. For example, many patients with PD
show freezing of gait, which is a feeling that the patient’s feet
are glued to the ground. Studies have shown both dopamine
and norepinephrine play a role in the occurrence of freezing of
gait in PD patients (Bohnen et al., 2011; Lewitt, 2012). A recent
computational model of freezing of gait in PD patients was able
to shed a light on how alterations to these neurotransmitters
impact gait function (Muralidharan et al., 2014). One limitation
of this model, however, is it did not explain how connectivity loss
among the cortex and basal ganglia can lead to freezing of gait.
Another common symptom in PD is dyskinesia, which is
often associated with long-term use of dopamine medications
(Bohnen et al., 2011), and occurs in over a quarter of
patients with PD (Fabbrini et al., 2007). Many brain regions
are implicated in the occurrence of dyskinesia, including
the striatum or subthalamic nucleus (Soghomonian, 2006),
prefrontal cortex (Cerasa et al., 2012), cerebellum (Kishore
and Popa, 2014), and premotor cortex (Halje et al., 2012;
Richter et al., 2013). Further, recent studies have suggested
that dyskinesia in PD is likely related to abnormal changes in
medium spiny neurons in the striatum (e.g., loss of dendritic
spines), which is likely caused by impaired connectivity with
dopamine neurons (Villalba and Smith, 2010; Suárez et al.,
2014). This is in agreement with studies showing that both
dopamine D1 and D2 receptors play a role in dyskinesia (Iravani
et al., 2012). By using connectivity analyses, it was found
that dyskinesia in PD is associated with altered connectivity
between the striatum and primary motor cortex (Herz et al.,
2015). Many neurotransmitters have been also implicated
in the occurrence of dyskinesia in PD including serotonin,
GABA, and glutamate (Bibbiani et al., 2005; Rylander et al.,
2010; Politis et al., 2014). Interesting, it has been difficult
to find treatment for dyskinesia in PD. However, it has
been demonstrated that dopamine D1 receptors are crucially
involved in levodopa-induced dyskinesia (Darmopil et al.,
2009). In addition, a recent study has found that downstream
regulatory element antagonistic modulator protein can also
reduce levodopa-induced dyskinesia in Parkinsonian animals
(Ruiz-DeDiego et al., 2015).
SCHIZOPHRENIA
Schizophrenia is a psychiatric disorder that can involve both
positive symptoms (such as delusions and hallucinations)
and negative symptoms (such as apathy, avolition and social
withdrawal). Unlike other brain disorders, schizophrenia is
often perceived to involve multiple and complex neural
dysfunctions (Honea et al., 2005). These include dysfunction to
the prefrontal cortex, basal ganglia, amygdala, and hippocampus
(Cohen et al., 1996; Wright et al., 2000; Allen et al., 2011;
Kühn et al., 2012; Yoon et al., 2013). It has been found
that dysfunction of dopaminergic neurotransmission is widely
observed in schizophrenia patients. However, dysregulation in
other neurotransmission including serotonergic and GABAergic
systems have been also reported (Carlsson et al., 2001; Abi-
Dargham et al., 2002; Faghihi and Moustafa, 2015). Studies have
shown reductions to regional brain volumes in patients with
schizophrenia, including cortical gray matter (Cahn et al., 2002),
medial temporal lobe and hippocampus (Wright et al., 2000;
Honea et al., 2005). One study has found increased coupling
between the posterior cingulate gyrus and precuneus in patients
with schizophrenia (Pu et al., 2014). In contrast, few studies have
dissociated positive and negative symptoms in schizophrenia
(Buchanan et al., 1993; Abi-Dargham, 2003; Cascella et al.,
2008; Arnedo et al., 2015). These studies suggested that positive
symptoms may be related to dysfunction in the basal ganglia and
hippocampus, while negative symptoms may be associated with
neural damage to the prefrontal cortex (Wolkin et al., 1992).
It is important to note that hallucinations and delusions are
often lumped together in one category, as measured by the
positive and negative syndrome scale (PANSS; Moritz et al.,
2001). However, based on studies from other patient populations,
Poletti et al. (2012) found that delusions and hallucinations often
do not co-exist in the same schizophrenia patient. To date, few
studies have focused on subcomponents of positive symptoms in
isolation. Bhatt et al. (2010) investigated cognitive dysfunction
in schizophrenia patients with and without delusions; they
found that the occurrence of delusions in schizophrenia is
associated with more false memory errors, possibly suggesting
that the hippocampus plays a role on both kinds of processes.
Other studies have also investigated hallucinations in isolation
(Hoffman et al., 2003; Schneider et al., 2011; Ford et al., 2014).
For example, it has been found that hallucinations are associated
with positive formal thought disorders (Sommer et al., 2010),
suggesting that these two symptoms may share neurobiological
substrates.
Using the psychiatric symptom rating scales (PSYRATS)
allowing for dimensional assessment of hallucinations and
delusions, Schneider et al. (2011), who dissociated the effects
of psychiatric treatment on delusions vs. hallucinations in
schizophrenia, found hallucinations tend to respond earlier to
antipsychotic treatment than delusions. Other studies show that
antipsychotic medications can reduce auditory hallucinations,
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while having minor effect on delusions (Lecrubier et al., 2007).
Given the dissociable effects of treatments on hallucinations and
delusions, it is likely that they are related to different neural
abnormalities. It is possible that hallucinations and delusions
are associated with separable neural systems, although some
argue that delusions (false beliefs) may cause hallucinations
(false perceptions; Maher, 1974; Ford et al., 2014). It is also
possible that hallucinations are related to perceptual dysfunction
(and thus impact posterior brain regions), while delusions are
related tomemory impairment (and thus related to temporal lobe
dysfunction). Further, hallucinations are often broken down into
subcategories (visual and auditory), as these present differently
in various disorders, such as PD and schizophrenia. Further,
it has also been argued that auditory hallucinations should be
subgrouped into internally perceived (e.g., thought echo) vs.
externally perceived (instructional voices; David, 2004), although
the dissociable neural substrates of each is not known.
Further, although it was found depression and apathy are
associated with different cognitive performances in PD (Pluck
and Brown, 2002; Oguru et al., 2010; Kirsch-Darrow et al.,
2011; Varanese et al., 2011), to our knowledge, dissociating
the two symptoms was not conducted in schizophrenia
studies. The findings that there are conflicting results of how
different antipsychotics may impact depressive and negative
symptoms in schizophrenia (Buckley and Stahl, 2007) could
be due to differential effects of antipsychotics on different
subcomponents of both general psychopathology and negative
symptoms subscales (for discussion, see Lecrubier et al., 2007).
In computational models of reinforcement learning, it has been
shown that schizophrenia patients have impaired performance at
acquisition of new knowledge on various reward and punishment
learning tasks. This effect has been attributed to impairments
of different aspects of the reward system (Somlai et al., 2011;
Moustafa et al., 2015). More specifically, Corlett et al. (2010)
have hypothesized that delusions arise from aberrations in how
individuals compute prediction error—the mismatch between
expectation and experience. They argue that defects in this
fundamental brain mechanism in cortical and subcortical brain
regions can vitiate perception, memory and social learning
causing delusional thinking in psychotic illnesses.
POSTTRAUMATIC STRESS DISORDER
PTSD is a fear and anxiety disorder, which develops in response
to exposure to a traumatic event (e.g., physical and sexual
assaults, combat experience, or motor vehicle accident) that
produce fear responses triggered by subsequent exposures to
reminders of the traumatic event (Gilbertson et al., 2008). Like
other brain disorders, PTSD is characterized by the occurrence
of different symptoms, including hyperarousal (e.g., problems
concentrating, sleep problems), avoidance (e.g., avoiding any
cues or contexts associated with the traumatic event), and re-
experiencing (e.g., the recurrence of negative thoughts associated
with the trauma; Gilbertson et al., 2008).
A wealth of data has shown that PTSD is associated
with damage to the amygdala, ventromedial prefrontal cortex,
hippocampus, and anterior cingulate (Gilbertson et al., 2008).
Specifically, it has been found that a smaller hippocampal area is a
risk factor for the development of PTSD (Gilbertson et al., 2002).
Other studies have also reported increased activation levels in the
amygdala, but reduced activation in the ventromedial prefrontal
cortex in PTSD patients (Gilbertson et al., 2002). However,
it remains unknown how these neural abnormalities relate to
different symptoms of PTSD.
Few studies have attempted to dissociate the effects of
PTSD symptoms, especially avoidance and re-experiencing.
For instance, Myers et al. (2012) found that re-experiencing
symptoms in PTSD is associated with impairment in
generalization of learned rules using the acquired equivalence
task (Kostek et al., 2014; Anastasides et al., 2015). This task has
two phases: acquisition (learning to associate two stimuli) and
transfer generalization (learning that cues become equivalent
when they were previously associated with the same response).
In this task, participants learn cues that were associated with
the same feedback acquire a similarity such that subsequent
generalization between these cues increases (Bondi et al., 1993).
Myers et al. (2012) found that avoidance symptoms in PTSD
are associated with behavioral inhibition. The same group
applied a probabilistic classification task with trials resulting
in reward, punishment and ambiguous outcomes (no-feedback
response) to male veterans with severe and few or no PTSD
symptoms. Those with severe PTSD symptoms outperformed
the patients with few or no PTSD on reward-based trials, while
there were no significant differences in punishment-based
trials. Furthermore, patients with less severe PTSD symptoms
rated ambiguous outcomes as more rewarding reflecting
successful avoidance (Myers et al., 2013). Additionally, Hopper
et al. (2007) also found that avoidance and re-experiencing
symptoms are associated with different neural abnormalities,
with avoidance severity negatively correlated with subcallosal
anterior cingulate activity, while re-experiencing severity
positively correlated with right anterior insula activity. Similarly,
Contractor et al. (2013) revealed that some PTSD symptoms
including dysphoria, avoidance and re-experiencing are related
to alterations in the behavioral inhibition system that guides
conflict resolution between approach and avoidance behaviors.
To our knowledge, no study has focused on understanding the
clinical and neural picture of hyperarousal in PTSD. Although
there have been computational models of fear conditioning
in PTSD (Moustafa et al., 2013b), none has attempted to
understand the neural and behavioral correlates of different
PTSD symptoms.
ALZHEIMER’S DISEASE
AD is the most common form of dementia in old age,
although it can also affect younger populations (Wilcock
and Esiri, 1982). Dementia (including AD) is an umbrella
term that involves loss of memory (semantic and episodic),
apraxia, changes in language understanding and production,
as well as executive dysfunction (Minati et al., 2009). Many
of these symptoms are often subcategorized into additional
subcomponents. For example, according to Cologne Apraxia
Screening test, apraxia involves deficits to limb imitation,
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pantomime of object use, and imitation of face postures. One
study suggested that apraxia has two components: commands to
pantomimemovements andmimickingmovements (Foster et al.,
1986).
Like most neurological and psychiatric disorders, AD is
associated with multiple neural abnormalities mostly affecting
the neocortex and hippocampal region (although there are
reports of dysfunction to other brain regions). Additionally, AD
is also associated with the formation of beta-amyloid plaques and
neurofibrillary tangles in the cortex and hippocampal regions
(Wilcock and Esiri, 1982) and a reduction of acetylcholine
levels in the hippocampus and cortex (Wilcock and Esiri, 1982).
Importantly, it is not known which neural damage gives rise to
which symptoms in AD.
Anterograde amnesia in AD has been shown to be related to
cortical abnormalities (Becker and Overman, 2002; Small et al.,
2003). These findings are in agreement with data showing that
the hippocampal region plays an important role in memory
acquisition and consolidation, while the neocortex accounts for
the maintenance of long-term memory (Squire and Alvarez,
1995). Several studies have investigated neural correlates of
language processing in AD (Whitwell et al., 2015). One study,
however, found that deficits in naming objects in AD are
associated with reduced activation of inferior temporal lobes
(Melrose et al., 2009).
To our knowledge, there is a dearth of studies investigating
clinical and therapeutic correlates of different symptoms in AD,
such as comparing memory severity to language dysfunction
in AD. There is, however, one recent study that investigated
neural correlates of subcomponents of apraxia, showing that
unlike pantomiming of object-use, limb imitation processes
are associated with underactivation to the inferior occipital
gyrus (Johnen et al., 2015). Unlike PD, there are almost
no studies that attempt to subcategorize AD patients into
subgroups to investigate clinical, neural, and therapeutic aspects
of each symptom in isolation. Further, unlike PD, there
are fewer numbers of computational models of AD, and to
our knowledge, few of them mainly focus on understanding
memory decline and learning deficits in AD. For example,
a network model by Ruppin and Reggia (1995) simulated
impairment in retrieval of recent memories in AD. Tippett
and Farah (1994) provided a feedforward connectionist model,
and showed that naming objects in AD patients is related to
semantic memory deficit in AD. Hasselmo (1997) provided a
hippocampus model showing that deficits in memory encoding
and retrieval in AD patients are possibly due to impaired
pattern separation of new and old inputs in the hippocampus.
In one study, deficits of acquired equivalent learning were
tested in patients with mild AD (Bódi et al., 2009). Acquired
equivalence, which is markedly impaired in case of hippocampal
damage (Myers et al., 2003), refers to the phenomenon in
which prior training to treat two stimuli as equivalent leads to
generalization between them, even if the stimuli are characterized
by superficial differences. Authors found that AD patients had
mild impairments in the training phase; however, they presented
profound deficits in the acquired equivalence task (Bódi et al.,
2009).
CONCLUSION
This article recommends a symptom-based, rather than whole
disease-based, approach to understand neural correlates of
neurological and psychiatric disorders (see Figure 1 for a
summary of results on the relationship between different
symptoms and neural substrates). As discussed above, some
studies have adopted this direction and investigated symptom
clusters separately, such as tremor in PD (Hess and Pullman,
2012; Zhang et al., 2015), positive and negative symptoms
in schizophrenia (Heckers et al., 1999), and psychomotor
retardation in depression (Liberg and Rahm, 2015). Yet, this
is not often the case for other symptoms or for other brain
disorders, such as PTSD and AD. Importantly, the approach
described here can be applied to other brain disorders, as most
disorders involve damage to different neural systems and are
associated with different clusters of symptoms. The challenge is
to map neural damage to symptom clusters.
It is important to note that the different symptoms in a
brain disorders are not necessarily dissociable (i.e., each is
associated with different neural substrates and clinical profile).
For example, some studies found that some motor symptoms
in PD correlate with each other, including hand movement,
gait and speech (Giladi et al., 2001; Goberman, 2005; Moreau
et al., 2007; Cantiniaux et al., 2010; Naismith and Lewis,
2010; Nutt et al., 2011; Skodda et al., 2011; Vercruysse
et al., 2012; Wagle Shukla et al., 2012). These correlations
suggest that pharmacological drugs may affect each cluster
of symptoms in a similar manner. Future studies should
investigate the relationships among the different symptoms in
a brain disorder; it is expected that related symptoms may
share similar neural mechanism and may benefit from same
treatment. For example, it was found that episodic memory
and executive function processes correlate in AD (Baudic
et al., 2006), but it is not known whether other symptoms in
AD correlate with each other (including language production
deficits and executive dysfunction). As we will discuss below,
future computational models should attempt to provide a
unified account of related symptoms, so they can provide
a plausible neural mechanism for symptoms. Importantly,
computational models can be used to provide best treatment
for brain disorders (see for example, a model of treatment
of schizophrenia symptoms by Siekmeier and vanMaanen,
2013).
A symptom-based approach will help us understand
commonalities among disorders. For example, depression is co-
morbid with many other disorders, including PD, schizophrenia,
among others, and it is possible that these all share a common
neural dysfunction. Depression in all these disorders have been
associated with decreased similar neural mechanisms, including
changes to dopamine and serotonin (Remy et al., 2005; Shen
et al., 2012). This approach is also in line with the Research
Domain Criteria (RDoC) project by the National Institute of
Health (NIH), which proposes to study information processing
mechanisms underlying single symptoms across different
disorders. For example, akinesia in PD and psychomotor
retardation in MDD are both associated with reduced dopamine
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FIGURE 1 | A summary of the relationship between different symptoms in brain disorders discussed here, and corresponding neural abnormalities.
A tick mark means the corresponding brain area plays a role in this symptom, while empty cells means either it does not, or no existing data on their relationship.
levels in the striatum, thus suggesting both may share a similar
mechanism.
Understanding the clinical picture and neural substrate of
each symptom may also help the development of treatment for
these symptoms. This may also help address conflicting results
in the literature regarding the effects of pharmacological drugs
on symptoms. For example, there have been conflicting results
on whether antipsychotics can ameliorate negative symptoms in
schizophrenia (Kane et al., 1988; Fitton and Heel, 1990; Miller
et al., 1994; Schooler, 1994; Klemm et al., 1996; Risch, 1996;
Rosenheck et al., 1997; Fink-Jensen, 2000; Rueter et al., 2004;
Horacek et al., 2006; Tamrakar et al., 2006; Buckley and Stahl,
2007; Curtis et al., 2008). This could be due the fact that negative
symptoms in schizophrenia are not monolithic constructs and
may vary from individual from another. This same analysis can
also be applied to other brain disorders.
It is important to note the process of subcategorizing a
symptom into several components is an ongoing process, and
future research is likely to further refine the subcategories of
symptoms in brain disorders. For example, hallucinations and
delusions are different classes of symptoms in schizophrenia,
and hallucinations can be subcategorized into internally or
externally perceived. The same applies to tremor, as it is often
subcategorized based on type (into resting tremor, action, or
postural tremor) or based on frequency (low or high) or
body part affected (neck, hand, or leg). As another example,
language deficits have been reported in AD, and it is likely
that subcategorizing language deficits into several components
may help understand the neural and therapeutic aspects of
each in isolation. Similarly, as reported above, few studies
have subcategorized apraxia in AD into motor processes that
involve either mimicking or pantomiming, and report that
these involve differential neural mechanisms (Foster et al.,
1986).
Understanding the neural correlates of a symptom does
not necessarily mean we understand its information processing
mechanism. This is important as it may help developing
a treatment for brain disorders (Siekmeier and vanMaanen,
2013). To do so, we must design a computational model to
understand how damage to some neural systems lead to these
symptoms. Computational models can aid in providing links of
brain-behavioral relationships in relation to neuropsychological
disorders. If dopamine is the main culprit in symptoms in PD,
computational models should be able to provide a mechanistic
account for how dopamine reduction cause these symptoms.
Importantly, computational models should be able to explain
how an increase or decrease in functional connectivity, regional
brain volume, or neurotransmitter levels relates to symptoms
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in different disorders. For example, a model can explain how
and why an increase (but not a decrease) in connectivity among
brain regions or neurotransmitter leads to certain symptoms.
Importantly, there have been some attempts to simulate different
symptoms in brain disorders. For example, some computational
models have simulated tremor in PD (Frank et al., 2007;
Shaikh et al., 2010; Dovzhenok and Rubchinsky, 2012), gait
dysfunction in PD (Muralidharan et al., 2014), hallucinations
and psychosis in schizophrenia (Ermentrout and Cowan, 1979;
Chen, 1995; Siekmeier et al., 2007; Lisman et al., 2010),
avoidance (main symptom in PTSD; Sheynin et al., 2015),
and language production deficits in AD (Conley et al., 2001).
Future computational modeling work should focus on simulating
other symptoms in these disorders as well as in other brain
disorders.
There have been other ways of subcategorizing psychiatric
and neurological disorders. For example, there are a few ways
to categorize AD using genetics, as AD patients are often
categorized in familial or sporadic, or into APOE ε4 carriers
or not (Duara et al., 1993; van Duijn et al., 1995). Further,
AD and PD are also often categorized into early vs. late-onset
(younger or older than 65 in AD and younger or older than 50
in PD; Koedam et al., 2010) or based on age of onset (Foltynie
et al., 2002). Other methods include disease duration and/or
disease severity, which is usually done in AD and PD research
as these are progressive disorders and symptoms change over
time. Although these are very useful and relatively easy to do,
subcategorizing a brain disorder based on symptoms has the
additional following benefits: (a) a symptom is a behavioral
trait and amenable to computational modeling and (b) many
symptoms (e.g., depression and anxiety) co-occur in various
brain disorders, so understanding these may help find treatment
to them regardless of the disorder.
To sum up, for each brain disorder, future work in cognitive
neuroscience, neuropsychology, and computational modeling
should: (a) investigate clinical profile of the different symptoms;
(b) study whether any of these correlate and thus related;
(c) test the effects of drugs on each symptom in isolation;
(d) investigate the neural substrates of each symptom; and
(e) design computational models to understand the neural
mechanism of each symptom in isolation. For example, a
model of a brain region (e.g., hippocampus) should be able to
explain all symptoms associated with hippocampus dysfunction,
including memory decline in dementia and delusions in
schizophrenia.
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